Q2 2023 Heron Therapeutics Inc Earnings Call
Participants
Craig Alexander Collard; CEO & Director; Heron Therapeutics, Inc.
Ira Duarte; Executive VP & CFO; Heron Therapeutics, Inc.
Jeff Cohn
William P. Forbes; Executive VP & Chief Development Officer; Heron Therapeutics, Inc.
Boris Peaker; MD & Senior Research Analyst; TD Cowen, Research Division
Carl Edward Byrnes; MD & Senior Research Analyst; Northland Capital Markets, Research Division
Serge D. Belanger; Senior Analyst; Needham & Company, LLC, Research Division
Yuxi Dong; Equity Associate; Jefferies LLC, Research Division
Presentation
Operator
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Second Quarter 2023 Earnings Conference Call. As a reminder, this conference is being recorded.
Now I would like to turn the call over to Jeff Cohn, Executive Director, Assistant General Counsel and Assistant Secretary. Please proceed.
Jeff Cohn
Thank you, Krista, and good afternoon, everyone. Thank you for joining us this afternoon on the Heron Therapeutics conference call to discuss the company's financial results for the second quarter ended June 30, 2023. With me today from Heron are Craig Collard, Chief Executive Officer; Ira Duarte, Executive Vice President, Chief Financial Officer; and Bill Forbes, Executive Vice President, Chief Development Officer.
For those of you participating via conference call, slides are made available via webcast and can also be accessed via the Investor Relations page of our website following the conclusion of today's call.
Before we begin, let me quickly remind you that during the course of this call, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the company's projections, expectations, plans, beliefs and future performance, all of which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995.
These statements are based on judgment and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties associated with the forward-looking statements made in this conference call and webcast are described in the safe harbor statement in today's press release and in Heron's public periodic filings with the SEC. Except as required by law, Heron assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so.
And with that, I would now like to turn the call over to Craig Collard, Chief Executive Officer.
Craig Alexander Collard
Thanks, Jeff. Good afternoon, everyone, and thank you for joining us today for our second quarter 2023 earnings call. I am pleased to share with you some significant developments that have transpired since our last call. Our team has been hard at work, and I'm excited to provide you with updates that we believe will lead to transforming Heron into a profitable company with growing revenues, including updates on our cost-reduction efforts, financing activities and changes in our executive management team as well as an update on the status of our pending Hatch-Waxman ANDA patent litigation.
On my first earnings call with Heron as CEO, I mentioned that I had only been here 4 weeks, and most of that time was used to assess the business and determine where we could make improvements quickly. The first step was assessing the executive leadership and making the proper changes that were needed. We made those changes, and we now have a leaner organization with a new CFO, Head of Development, Head of Supply and Vendor Management and new leadership in sales and marketing on the acute side of the business.
I am thrilled to announce that the new team has successfully implemented a cost-reduction initiative. Through careful analysis and strategic planning, we identified areas where we can streamline our operations and enhance efficiencies. Over the next 3 years, we expect to achieve a remarkable cash savings of approximately $75 million. This initiative reflects our commitment to fiscal responsibility and our dedication to optimizing our resources for sustained growth.
In addition to the cost-cutting measures, we were able to bolster the balance sheet by completing a $30 million equity financing with some of our largest shareholders as well as closing on an up to $50 million working capital facility. Based on our current operational plan, we expect that this will provide the company with enough capital to achieve profitability. This achievement underscores the confidence that our investors and partners have in our business strategy and growth potential of our products.
We are still in the early stages of revamping Heron into a commercially focused company with efficient operations. The changes we have made this quarter are significant and has certainly improved the business and set up a solid foundation for the future. The next phase of improvements will be focused around maximizing the growth potential of all of our products on both the acute care and oncology side of the business.
Even during this recent time of organizational change, the company is still seeing product growth. We expect this to improve dramatically as we implement new strategic plans moving forward.
Now moving on to some product highlights from the quarter. On the oncology side of the business, Q2 net product sales combined for CINVANTI and SUSTOL were $27.3 million, which increased from $25.1 million for the same period in 2022. We also grew combined sales by 6% quarter-over-quarter.
We are pleased to reiterate our financial guidance for the oncology franchise of $99 million to $103 million in net product sales for the full year 2023. We also recently had a favorable outcome at the Markman hearing in our pending Hatch-Waxman ANDA litigation against Fresenius to enforce our CINVANTI patents. We are pleased with the outcome, and we'll continue to vigorously enforce and defend our patent portfolio.
Moving now to the acute care side of the business with ZYNRELEF and APONVIE. We continue to see product growth on this side of the business also, even though we have yet to implement many of our planned changes. Once we accomplish many of the initiatives focused on improving the fundamentals of how we conduct our business, we plan to then move forward with some of the transformational initiatives.
Net product sales of ZYNRELEF for the quarter were $4.2 million compared to $2.5 million for the same period in 2022. Quarter-over-quarter unit growth was 11%. Net product sales of APONVIE for the quarter were $300,000. APONVIE became commercially available in the U.S. on March 6, 2023. During this launch phase, we are receiving very positive feedback from some customers due to APONVIE's unique clinical value. In fact, several hospital systems have already adopted for all moderate/severe patients and many others have been currently scheduled for system-wide review.
The next phase of business improvement will be focused around product growth and maximizing the value of our assets. With ZYNRELEF, we have 3 key initiatives underway to expand our business, including our filed sNDA, the vial access needle, or VAN, and a prefilled syringe. ZYNRELEF is a unique product true 72-hour pain relief. It also has pass-through reimbursement status, allowing our product to be separately reimbursed outside of the surgical bundle in both hospitals and ASCs.
All of these product improvements and attributes are part of the new overall company and product strategy and should have a dramatic impact to our growth over the next several years. This growth will not take place overnight, but our products have a great clinical profile, excellent reimbursement status and with the right commercial plan, we should begin to see massive improvement that will ultimately lead the company to profitability.
Regarding the sNDA for our label expansion for ZYNRELEF, we were recently informed by the FDA of a 3-month extension of our PDUFA date from October 23, 2023 to January 23, 2024. The division became aware of our time line for some new nonclinical data the company was completing and in the spirit of cooperation, we agreed to submit this new data to the division. The division deemed the submission to be a major amendment to our sNDA and accordingly extended the review period by 3 months.
In conclusion, the past quarter has been marked by significant accomplishments and strategic moves that will undoubtedly shape the trajectory of our company. The successful implementation of our cost-reduction initiatives, the securing of debt and equity financing, the favorable outcome at the CINVANTI Markman hearing and the strengthening of our executive management team all position us for continued success and growth. While this business will not be transformed overnight, 2023 will prove to be a turnaround year for Heron. Thank you for your patience and continued support of the company as we move through this transition.
I will now turn the call over to Ira Duarte, our CFO. Go ahead, Ira.
Ira Duarte
Thanks, Craig. Our combined product net revenues for the second quarter of 2023 were $31.8 million compared with $27.6 million in Q2 2022, representing an increase of 15% to the same period of 2022. Product net revenues for the first 6 months of 2023 were $61.4 million compared with $51.1 million for 2022 or an increase of 20%.
Our acute care franchise net revenues for the 3 and 6 months ended June 30, 2023, were $4.5 million and $8.3 million, respectively, which increased from $2.5 million and $3.5 million, respectively, for the same period in 2022. For the 3 and 6 months ended June 30, 2023, oncology care franchise net product sales were $27.3 million and $53.1 million, respectively, which increased from $25.1 million and $47.5 million, respectively, for the same period in 2022.
Our product gross profit for the quarter was $11.6 million and $24.4 million for the 6 months ended June 30, 2023, representing 36.5% and 40% of net revenue, respectively. These margins were negatively impacted by a write-off of ZYNRELEF inventory in both Q1 and Q2 of 2023. We believe these margins will improve and stabilize as we are working through some of our ZYNRELEF inventory. We also had a number of initiatives we are working through that we will discuss on future earnings call that should have a very positive impact on costs moving forward.
SG&A expense for Q2 and 6 months ended June 30, 2023, were $36.4 million and $68.4 million, respectively, compared to $32.1 million and $64.1 million in the same period of 2022 with the increase primarily resulting from our reduction in force announced in June 2023. Research and development expenses were $17.6 million and $31.4 million in Q2 and 6 months ended June 30, 2023, compared to $28.8 million and $70.9 million in the comparable period of 2022. The decrease in the spend was primarily related to decreases in costs related to ZYNRELEF as production scale up, validation activities and raw materials qualifications were completed in 2022.
In addition, overall personnel and related costs decreased due to the reduction in force implemented in June 2022. We believe we can continue to reduce costs moving forward in this area as we continue to increase efficiency.
The operating loss for the quarter was $42.4 million compared with $49.5 million in Q2 2022, and the net loss was $42.1 million for Q2 2023 and $56.4 million for the comparable period in 2022.
Looking to total year-to-date net loss. 2023 is a net loss of $74.8 million compared with $120.2 million in the comparable period of 2022. Our balance sheet at the end of June 30, 2023, shows a cash and short-term investment balance of $33.2 million. However, as Craig mentioned in his earlier comments, we closed the capital raise of approximately $30 million in July 2023 and a working capital facility of up to $50 million in August 2023. These financings, combined with our cost-savings initiatives, position us for future growth and a path to profitability.
Back to you, Craig.
Craig Alexander Collard
Thanks, Ira. Operator, at this time, we'd like to open the line for questions.
Question and Answer Session
Operator
(Operator Instructions) Your first question comes from the line of Serge Belanger from Needham & Company.
Serge D. Belanger
Just a couple of questions for us. First one, regarding achieving profitability. I think in the past, you've talked about a late 2024 time line. So that -- is that still the target? Or has that changed given the regulatory delay around ZYNRELEF? And maybe if you can talk about the assumptions on how we get there. And I guess, secondly, regarding that regulatory delay for ZYNRELEF, maybe just talk about what you expect the label expansion could look like once it gets approved.
Craig Alexander Collard
Serge, thanks for the question. So regarding profitability, again, we have said that we believe we would achieve profitability in late 2024. I think the takeaway here is based on the money we've raised, again, we don't think we'll need to raise any more monies in order to get to that point. And we built that forecast without the upside of the sNDA for the VAN or anything like that. So this is more of just a trend forecast on how the product was performing.
And so with the cost-reduction efforts we've made, we are able to get to profitability within that time frame. There could be some upside from some things we're doing. Again, assuming we get the label expansion, we're anticipating -- assuming that some of the things that we implement will have a positive impact on ZYNRELEF when those types of things happen and APONVIE as well. So from that standpoint, that's how we're getting to profitability into '24.
Regarding the sNDA and the expansion, I'd like to -- Bill Forbes is here with us in the room, and I'd like maybe him to speak in a little bit more detail around that and his thoughts.
William P. Forbes
Thanks, Craig. This is Bill Forbes. Yes, so the current package insert allows for periarticular installation for up to 72 hours of analgesia with bunionectomy, open in wind herniorrhaphy and total knee Arthroplasty. What we're proposing in the sNDA is that we go to postsurgical analgesia for soft tissue in orthopedic.
So maybe I'll step back a little bit here and just kind of talk broadly about the vision that was put in here at Heron. And ZYNRELEF has actually been studied in 14 clinical trials. 8 unique surgical procedures were contributing to those 14 clinical trials: 4 soft tissue and 4 different orthopedic surgical procedures.
So when the supplement went in and actually went in with data from lumbar biosurgery, total shoulder surgery, mammoplasty, C-section, abdominoplasty. The lumbar spinal surgery and total surgery has actually already been presented at Western and Southern ortho conferences. So that data has already been put out there. And I think in many respects, this is going to broaden our label. Hopefully, we can negotiate a favorable label expansion with this data.
I'm going to talk a little bit about what happened with the major amendment. We had been doing and continue to do some studies and some of those preclinical, and we were doing a rabbit study that looked a little further out. This was for intra-articular injection. As I've mentioned before, the indication for ZYNRELEF is actually periarticular, not intra-articular. So the label itself actually cautions physicians about the use of using intra-articular. And I think from that perspective, we consider this class labeling.
This particular rabbit study just looked out a little bit further, so while it is new data, it is not actually a new finding and it's already accounted for in our label. So I think that was kind of a disappointment on our side. We didn't feel like it was -- it needed -- that the agency or the division needed to declare a major amendment or -- to this particular filing because of that. So hopefully, that answers your question.
Operator
Your next question comes from the line of Boris Peaker from TD Cowen.
Boris Peaker
Two questions on my end. First, in terms of profitability. I'm just curious, Craig, do you think Heron can become a profitable organization based on supportive care alone? Like if we exclude ZYNRELEF, is there an opportunity to restructure it such just to profitability without ZYNRELEF?
Craig Alexander Collard
We really hadn't looked at it that way. But I mean, again, now you're talking if we put total focus around APONVIE and didn't promote ZYNRELEF at all, I mean, I think we would have obviously some inventory problems and that type of thing. But we really haven't analyzed it that way. But again, we're not looking for superior growth or anything with ZYNRELEF.
From a profitability standpoint, we're really only trending the product on the current growth trajectory it's on. So again, I think there's some upside there. And again, we've been pretty conservative well with APONVIE. And I think our one surprise is that we still are getting really good results out of CINVANTI. So I think there's an upside here that we really haven't accounted for.
But I think the point of this that we've been really trying to communicate is that we wanted transparency in the fact that we're trying to divi this business and put a cost reduction in place that allows us to get to profitability and be fairly conservative about our outlook.
Boris Peaker
Great. And on ZYNRELEF, specifically, then. You've obviously talked about the 3 indications where it's currently approved and the label expansion path going forward. But within the approved indications, do you have a sense of where the sales are coming from right now? Just trying to better understand why it may be used in certain areas versus not others.
Craig Alexander Collard
Yes. I think where we've had the most success up to this point has really been within knee and hip. I mean that's where a majority of the procedures are being performed. And again, once these hospitals or ASCs get passed sort of the prep issue, we're seeing data that suggest once we have a sort of 4-month usage, we typically keep those customers. So that's where we've had the most success to date.
Operator
(Operator Instructions) We have no further questions in the queue at this time -- oh, I'm sorry, we do. Carl Byrnes from Northland Capital Markets.
Carl Edward Byrnes
Congratulations on the progress. Any thoughts with respect to ZYNRELEF in terms of potential partnership? And what might that look in terms of accelerating and leveraging your existing sales force? And then I have a follow-up as well.
Craig Alexander Collard
Well, thanks, Carl. Sorry, we almost cut you off there, so I apologize for that. Yes, one of the things we've been looking to do is what can we do outside of things that were used as far as improving ZYNRELEF like targeting and using better data, position our reps, maximizing territory potential and so on and so forth. We've been looking at possibilities to partner this product.
The biggest issue with ZYNRELEF is not the clinical story. The true 72-hour pain relief is a big thing. And as we look at market research and that type of thing, that seems to -- we have no issue there. And I think we've had really good success.
The issue has been with the preparation of the product in the surgical suite itself. And the issue with that is the nonsterile environment and then just the time that it takes to pull the product out of the bottle. And so we've been looking at a number of different surgical companies that would be distributors, if you will, and that we could partner with who are pretty much living in those surgical suites on a daily basis.
I know some of our competitors have done that. And we think by picking it harder in the surgical suite, it would allow our reps to, one, spend more time with physicians detailing the product, but also frees them up a bit to do other things with APONVIE and CINVANTI. And number 2 thing would be give a lift to those products as well. So I think you'll see over the next fairly short time frame, we will pick a partner of some sort that will add to our footprint with ZYNRELEF, and I think it should be from the [low] side of the product. And again, these are things that we have not forecasted.
Carl Edward Byrnes
Got it. And then kind of switching gears a little bit. If we look at SG&A, which is around, I think, around $36.4 million and R&D at $17.6 million, can you quantify how much in the quarter was related to severance and potentially kind of onetime extraordinary-type charges and what you expect the expense levels to be if you're able to comp out for the third quarter? Or if that's not possible or -- do you expect additional onetime severance and onetime-type charges to hit the third quarter?
Ira Duarte
Yes. We -- I think we publicly released, we have about $5.9 million in a onetime charge that will come through to the end of this year. So going to 2024, you will see our operating expenses, there's been a bounce leveling out at $120 million for the year, $120 million in 2024. And we believe we can cut out another $10 million off that going forward.
Operator
(Operator Instructions) Your next question comes from the line of Kelly Shi from Jefferies.
Yuxi Dong
This is Clara on for Kelly. So I have 2 questions. For APONVIE, so this is the first full quarter of sales. Seems like you had a lot of positive feedback from physicians. So just wondering how should we think about the sales growth trajectory from now on for APONVIE.
Craig Alexander Collard
Yes. No, it's a great question. We haven't had a ton of time with APONVIE, but the biggest difference with APONVIE versus ZYNRELEF is that when we get an IDN or a formulary win with ZYNRELEF, it's still going to take quite a bit of work with individual surgeons and that type of thing. It's not necessarily a systemwide conversion.
The difference with APONVIE is that there are situations where we can get system-wide conversion. And what I mean by that, if you take a hospital system, say like Baylor, and we were to selectively get moderate-to-severe patients, we can really get all of those patients, so all high-risk patients, maybe in the situation they convert to APONVIE and the Epic system and so forth. So we get a system win that leads to sort of a conversion, if you will.
And so I think what you'll find over the next few quarters is that we'll begin to get the systemwide orders that create bigger revenues, almost annuities, if you will, in certain accounts going forward. We've had a couple of hospital systems to date that have converted. You haven't really seen that in the results yet, but you'll begin to see it. And I think we have another 23 systems right now that are in review.
So again, we really like the progress. I think it's going to take a little more time, obviously, to see the results from that. But again, in a very short time period, I think you're going to begin to see some of these more, if you will, bigger orders that come through. And ideally, what we want to do as we report going forward, we'll try to give a little more insight in the pipeline hospital wins and that type of thing. That way, we'll have a bit more transparency in what's really going on with the product.
Yuxi Dong
Great. And also for ZYNRELEF, also curious, have you seen -- or had different physician feedback on ZYNRELEF in terms of different kinds of surgical indications? And also understanding that, that could be available by mid-2024. How quickly do you think we can see the change on sales growth trajectory after the VAN launch? And what kind of efforts are you making between now and that launch for sales improvement?
Craig Alexander Collard
Yes. Well, I think the good news is the VAN is on track from a time line perspective. We do believe we'll have that out in midyear of next year. And it does 2 things. One, it helps with the sterility issue. It makes that much simpler. And two, it's going to change the time to pull the product. So instead of 3 to 4 minutes, it could be upwards of 20 to 30 seconds. And so I think it's dramatically going to impact the product from a standpoint of just ease of use.
Again, our -- I mentioned before about looking to possibly partner with a surgical partner in the surgical suite. I think that's something as well as we lead into the VAN and with an expanded label and hopefully expanded footprint. All of those things should lead to higher sales and higher sales growth.
But again, I want to reiterate, we have not forecasted that as far as getting us to profitability. These would be additional sales. So we feel pretty comfortable with that. And again, everything seems to be on track from a time line perspective.
Operator
We have no further questions in the queue at this time. Craig, I'll turn it back to you for closing remarks.
Craig Alexander Collard
I just want to thank everyone again. This is our second earnings call, but we really do appreciate the time and patience. I think the business is making some strides in transforming. It's going to take a little bit of time, but we're getting there. And I think we've had some significant things that have happened this quarter. So we look forward to updating everyone next quarter. Thank you.
Operator
Ladies and gentlemen, this concludes today's conference call. Thank you for your participation, and you may now disconnect. Goodbye.
